Abstract
Understanding of the full potential of the genome coding capacity demands a deep knowledge of the different pathways that control gene expression. Translation initiation in eukaryotic mRNAs is a highly regulated process that accounts for the last step of gene expression control. While most mRNAs initiate translation using the AUG triplet closest to the 5end, a growing number of mRNAs appear to follow different rules, giving rise to proteins that differ in their amino terminus. Internal ribosome entry site (IRES) elements provide an alternative to initiate translation that allow the use of internal start codons, sometimes located several hundred of residues away from the 5end of the mRNA, bypassing strong RNA structures. Therefore, they represent a strategy to increase genetic diversity without increasing genome length. The IRES sequences found in viral and cellular mRNAs do not show overall sequence similarity, albeit they perform a similar function. IRES elements in viral mRNAs constitute an efficient method to distinguish its own mRNA from that of the host, and thus facilitate its survival when cellular protein synthesis is impaired. Viral IRES exploit different strategies to recruit the translational machinery, including direct ribosome binding, eIF3 or eIF4G-mediated mechanism. Cellular IRES mediated-translation represents a regulatory mechanism that helps the cell to cope with transient stress. They may be grouped according to common tropism, stimulation by similar situations and expression of specific targets in differentiated cells. Protein mediated-ribosome binding is likely to enhance the efficiency of cellular IRES sequences under specific environments. This review is focused to discuss recent advances on functional IRES elements.
Keywords: mrna, ires, protein synthesis, new orfs, genetic diversity, eukaryotic genomes
Current Genomics
Title: Internal Ribosome Entry Site Elements in Eukaryotic Genomes
Volume: 5 Issue: 3
Author(s): E. Martinez-Salas, O. Fernandez-Miragall, R. Reigadas, A. Pacheco and P. Serrano
Affiliation:
Keywords: mrna, ires, protein synthesis, new orfs, genetic diversity, eukaryotic genomes
Abstract: Understanding of the full potential of the genome coding capacity demands a deep knowledge of the different pathways that control gene expression. Translation initiation in eukaryotic mRNAs is a highly regulated process that accounts for the last step of gene expression control. While most mRNAs initiate translation using the AUG triplet closest to the 5end, a growing number of mRNAs appear to follow different rules, giving rise to proteins that differ in their amino terminus. Internal ribosome entry site (IRES) elements provide an alternative to initiate translation that allow the use of internal start codons, sometimes located several hundred of residues away from the 5end of the mRNA, bypassing strong RNA structures. Therefore, they represent a strategy to increase genetic diversity without increasing genome length. The IRES sequences found in viral and cellular mRNAs do not show overall sequence similarity, albeit they perform a similar function. IRES elements in viral mRNAs constitute an efficient method to distinguish its own mRNA from that of the host, and thus facilitate its survival when cellular protein synthesis is impaired. Viral IRES exploit different strategies to recruit the translational machinery, including direct ribosome binding, eIF3 or eIF4G-mediated mechanism. Cellular IRES mediated-translation represents a regulatory mechanism that helps the cell to cope with transient stress. They may be grouped according to common tropism, stimulation by similar situations and expression of specific targets in differentiated cells. Protein mediated-ribosome binding is likely to enhance the efficiency of cellular IRES sequences under specific environments. This review is focused to discuss recent advances on functional IRES elements.
Export Options
About this article
Cite this article as:
Martinez-Salas E., Fernandez-Miragall O., Reigadas R., Pacheco A. and Serrano P., Internal Ribosome Entry Site Elements in Eukaryotic Genomes, Current Genomics 2004; 5 (3) . https://dx.doi.org/10.2174/1389202043349390
DOI https://dx.doi.org/10.2174/1389202043349390 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Deep learning in Single Cell Analysis
The field of biology is undergoing a revolution in our ability to study individual cells at the molecular level, and to integrate data from multiple sources and modalities. This has been made possible by advances in technologies for single-cell sequencing, multi-omics profiling, spatial transcriptomics, and high-throughput imaging, as well as ...read more
New insights on Pediatric Tumors and Associated Cancer Predisposition Syndromes
Because of the broad spectrum of children cancer susceptibility, the diagnosis of cancer risk syndromes in children is rarely used in direct cancer treatment. The field of pediatric cancer genetics and genomics will only continue to expand as a result of increasing use of genetic testing tools. It's possible that ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
DNA Topoisomerase II Enzymes as Molecular Targets for Cancer Chemotherapy
Current Cancer Drug Targets Nanotechnology on Duty in Medical Applications
Current Pharmaceutical Biotechnology Need to Think Outside Organ-based Diagnosis to Molecular Diagnostics
Applied Clinical Research, Clinical Trials and Regulatory Affairs Recent Patents in Antiviral siRNAs
Recent Patents on Anti-Infective Drug Discovery Microgravity Alters Cancer Growth and Progression
Current Cancer Drug Targets Asthma, Allergy and Chemokines
Current Drug Targets Novel Insights into Targeting ATP-Binding Cassette Transporters for Antitumor Therapy
Current Medicinal Chemistry Long Noncoding RNA GAS5: A Novel Marker Involved in Glucocorticoid Response
Current Molecular Medicine Recent Advances in Regulatory T Cell Therapy of Autoimmunity, Graft Rejection and Cancer
Recent Patents on Inflammation & Allergy Drug Discovery Refractory Chronic Lymphocytic Leukemia: A Therapeutic Challenge
Current Cancer Drug Targets Preferentially Expressed Antigen in Melanoma (PRAME) and the PRAME Family of Leucine-Rich Repeat Proteins
Current Cancer Drug Targets Prodrugs and Endogenous Transporters: Are They Suitable Tools for Drug Targeting into the Central Nervous System?
Current Pharmaceutical Design The Mevalonate Pathway as a Therapeutic Target in the Ph-Negative Chronic Myeloproliferative Disorders
Current Drug Targets Secondary Metabolites from Cordyceps Species and Their Antitumor Activity Studies
Recent Patents on Biotechnology Inhibitors of Apoptosis Proteins (IAPs) as Potential Molecular Targets for Therapy of Hematological Malignancies
Current Molecular Medicine Involvement of Targeting and Scaffolding Proteins in the Regulation of the EGFR/Ras/MAPK Pathway in Oncogenesis
Current Signal Transduction Therapy Therapeutic Value of Black Seed Oil in Methotrexate Hepatotoxicity in Egyptian Children with Acute Lymphoblastic Leukemia
Infectious Disorders - Drug Targets Bench to Bedside Targeting of FLT3 in Acute Leukemia
Current Drug Targets (Review Article) Screening for Disease-Markers and Investigating Drug Effects by Proteome Profiling: Can it Meet Expectations?
Combinatorial Chemistry & High Throughput Screening NF-κB Blockers Gifted by Mother Nature: Prospectives in Cancer Cell Chemosensitization
Current Pharmaceutical Design